drugset / Trial / NCT01189175

Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823

NCT01189175

Phase 1 Completed 16 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of the study is to investigate whether ketoconazole affects plasma exposure of BI 113823

Timeline

Start
2010-08
Primary completion
2010-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 113823 Unknown 50 mg Oral
Subject Ketoconazole Small molecule 200 mg Oral

Indications

No indication recorded.